November 9, 2015 – Executive recruiters Slone Partners has placed Dr. Richard Bender as chief medical officer at Signal Genetics, a commercial stage, molecular genetics diagnostic company located in Little Rock, AR.
Dr. Bender has spent 25 years in clinical practice the majority spent serving as the medical director for oncology / hematology for Kaiser Permanente in San Diego. In 2002 he transitioned to the diagnostic industry where he has been the medical director for hematology / oncology for Quest Diagnostics, Inc. and the chief medical officer for Agendia, a molecular diagnostics company. He has also served on the executive board of the San Diego Hospice and American Cancer Society. He continues to teach at the UCLA School of Medicine, as well as to serve as an expert reviewer in oncology for the medical board of California and was recently selected to be a consultant for the Medical Devices Advisory Committee of the FDA.
“Dr. Bender has significant experience in both laboratory diagnostics and drug development, which will further enhance our senior management team as we work to expand our test menu and the services that we provide,” said Samuel D. Riccitelli, president and chief executive officer. “With our continued growth, it is critically important that we attract leaders who are experts in our space, and who share our passion for improving the treatment of patients. Slone Partners’ knowledge of this industry has been an important success factor in attracting high quality individuals to our organization.”
“It was important to us that we approached our partnership strategically from the beginning, so we could ensure long term success,” said CEO Adam Slone. “Signal Genetics is doing great work in improving patient care, and we are committed to a strong partnership as they continue to grow.”
Healthcare is among the most rapidly growing employment fields. The increasing number of people insured through the Affordable Care Act has created additional demand for health service. But the industry is in the midst of a turbulent transformation, making the need for proven and experienced boards and executive teams with vision more important than ever.
Over the past several months, Slone Partners has recruited a chief clinical laboratory officer for personalized medicine company Celmatix; a vice president of research, development & engineering at medical technology incubator Cirle; a VP of managed care at medicine company Genomind, and president of North America at cancer detection company Abcodia.
The firm is a nationally-recognized recruitment firm that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C. and San Francisco.
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media